Patent Baristas

John J. Doll, Commissioner for Patents, US Patent & Trademark Office, talked today at the BIO Intellectual Property Counsel Committee’s Fall Conference and Committee Meeting, a group with a very keen sense of the importance of patents. He livened up the discussion in extolling that “We [the Patent Office] don’t have a standard so we’d […]

In a session on Case Law Updates, a panel discussion at the the BIO Intellectual Property Counsel Committee’s Fall Conference and Committee Meeting brought up that there was previously a lot of attention on infringement but lately it has been off radar except for joint joint infringement. Joint infringement comes up as a big issue […]

In a session on Case Law Updates at the the BIO Intellectual Property Counsel Committee’s Fall Conference and Committee Meeting, Chad Shear led a panel discussion with John Dragseth and Dr. John Garvish through a discussion of Bilski and how we got to Bilski.  The case, involved a patent application seeking exclusive rights to a […]

Pointing out that Senators Obama and McCain agree on the need for affordable biologic medicines, Biologicsland now offers a game for testing your knowledge about biogenerics. Biologicsland, brought to you by Teva Pharmaceuticals, is an on-line board game where you pick a person to act as your player, like politician or scientist (and why is […]

The Biotechnology Institute is now accepting applications for “BioNOW” (Biotechnology Network of Women,) a leadership training program for women biotechnology professionals. The Biotechnology Institute is partnering with biopharmaceutical company Nektar Therapeutics for the program. BioNOW, which will be held December 4-5 at Nektar’s headquarters in San Carlos, CA, will allow participants to develop skills that […]

It appears that no matter who wins the presidential election this November, both Barack Obama and John McCain back expanded use of generic drugs as a way to lower drug costs,  According to their advisers, both campaigns have pledged their support to help create a market for generic biotech drugs or biosimilars. As a part […]

here at Patent Baristas, we get all giddy when a case comes down the pike involving protein synthesis and gene cloning vectors.  It doesn’t happen all that often and, when it does, we’re treated to BIO 101 introductions explaining how proteins are biomolecules that “are encoded by particular deoxyribonucleic acid (“DNA”) sequences known as genes.” […]

Today’s Washington Post features a story on Ismed’s efforts to promote a follow-on biologics approval pathway here in Washington.  The article outlines the campaign by Insmed’s chief exec, Geoffrey Allan, to give Congress a lesson in biotechnology. The sudden outpouring of educational efforts on protein structures and drug pharmacology has to do with the fact […]